Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.21.2
Revenue (Tables)
9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues From Licensing Agreements and Strategic Partnerships
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended September 30, Nine Months Ended September 30,
  2021 2020 2021 2020
Seagen $ (280) $ 366  $ 424  $ 9,326 
AstraZeneca 1,607  2,182  18,309  7,227 
Servier 1,867  391  3,379  10,893 
Genentech 863  —  863  — 
Total Revenue $ 4,057  $ 2,939  $ 22,975  $ 27,446 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,096  $ 4,275 
Servier 139  209 
Seagen 754  450 
Boston Pharmaceuticals 88  265 
Genentech 834  600 
Total potential milestone payments $ 2,911  $ 5,799